APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurokinin Receptor Antagonists API Market Outlook and Growth Opportunities 2026

29 December 2025211 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists API Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists API Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists API Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists API Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurokinin Receptor Antagonists API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurokinin Receptor Antagonists API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurokinin Receptor Antagonists API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurokinin Receptor Antagonists API market include Zhejiang Tiantai Pharmaceutical, Humanwell Pharmaceutical, Viwit, Sichuan Qingmu Pharmaceutical, Kelun Pharmaceutical, Shandong New Time Pharmaceutical, Shandong Anxin Pharmaceutical, Qilu Pharmaceutical and Luoxin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurokinin Receptor Antagonists API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurokinin Receptor Antagonists API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurokinin Receptor Antagonists API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurokinin Receptor Antagonists API market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurokinin Receptor Antagonists API Segment by Company

Zhejiang Tiantai Pharmaceutical

Humanwell Pharmaceutical

Viwit

Sichuan Qingmu Pharmaceutical

Kelun Pharmaceutical

Shandong New Time Pharmaceutical

Shandong Anxin Pharmaceutical

Qilu Pharmaceutical

Luoxin Pharmaceuticals

Lianyungang Runzhong Pharmaceutical

Wisdom Pharmaceutical

Hansoh Pharma

United Pharma

Hangzhou Jiuyuan Gene Engineering

Beijing Sjar Technology Development

Zydus Animal Health And Investments

Taizhou Crene Biotechnology

Solara Active Pharma Sciences

Procos

Piramal Pharma

Optimus Pharma

Murli Krishna Pharma

MSN Laboratories

Jubilant Pharmova

Helsinn Advanced Synthesis

Glenmark Life Sciences

Dr. Reddy's Laboratories

Clearsynth Labs

Camus Pharma

Andenex

Neurokinin Receptor Antagonists API Segment by Type

Aprepitant

Fezolinetant

Fosaprepitant

Rolapitant

Maropitant

Netupitant

Neurokinin Receptor Antagonists API Segment by Application

Injections

Tablets

Oral Suspension

Capsules

Other

Neurokinin Receptor Antagonists API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurokinin Receptor Antagonists API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurokinin Receptor Antagonists API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurokinin Receptor Antagonists API significant trends, drivers, influence factors in global and regions.

6. To analyze Neurokinin Receptor Antagonists API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurokinin Receptor Antagonists API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurokinin Receptor Antagonists API industry.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurokinin Receptor Antagonists API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurokinin Receptor Antagonists API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurokinin Receptor Antagonists API Industry Trends Table 2. Neurokinin Receptor Antagonists API Industry Drivers Table 3. Neurokinin Receptor Antagonists API Industry Opportunities and Challenges Table 4. Neurokinin Receptor Antagonists API Industry Restraints Table 5. Global Neurokinin Receptor Antagonists API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurokinin Receptor Antagonists API Revenue Share by Company (2021-2026) Table 7. Global Neurokinin Receptor Antagonists API Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Neurokinin Receptor Antagonists API Sales Volume Share by Company (2021-2026) Table 9. Global Neurokinin Receptor Antagonists API Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Neurokinin Receptor Antagonists API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurokinin Receptor Antagonists API Key Company Manufacturing Base & Headquarters Table 12. Global Neurokinin Receptor Antagonists API Company, Product Type & Application Table 13. Global Neurokinin Receptor Antagonists API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurokinin Receptor Antagonists API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Aprepitant Table 18. Significant Companies of Fezolinetant Table 19. Significant Companies of Fosaprepitant Table 20. Significant Companies of Rolapitant Table 21. Significant Companies of Maropitant Table 22. Significant Companies of Netupitant Table 23. Global Neurokinin Receptor Antagonists API Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 24. Global Neurokinin Receptor Antagonists API Sales Volume by Type (2021-2026) & (Tons) Table 25. Global Neurokinin Receptor Antagonists API Sales Volume by Type (2027-2032) & (Tons) Table 26. Global Neurokinin Receptor Antagonists API Sales Volume Share by Type (2021-2026) Table 27. Global Neurokinin Receptor Antagonists API Sales Volume Share by Type (2027-2032) Table 28. Global Neurokinin Receptor Antagonists API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Neurokinin Receptor Antagonists API Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Neurokinin Receptor Antagonists API Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Neurokinin Receptor Antagonists API Sales Value Share by Type (2021-2026) Table 32. Global Neurokinin Receptor Antagonists API Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Injections Table 34. Significant Companies of Tablets Table 35. Significant Companies of Oral Suspension Table 36. Significant Companies of Capsules Table 37. Significant Companies of Other Table 38. Global Neurokinin Receptor Antagonists API Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 39. Global Neurokinin Receptor Antagonists API Sales Volume by Application (2021-2026) & (Tons) Table 40. Global Neurokinin Receptor Antagonists API Sales Volume by Application (2027-2032) & (Tons) Table 41. Global Neurokinin Receptor Antagonists API Sales Volume Share by Application (2021-2026) Table 42. Global Neurokinin Receptor Antagonists API Sales Volume Share by Application (2027-2032) Table 43. Global Neurokinin Receptor Antagonists API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Neurokinin Receptor Antagonists API Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Neurokinin Receptor Antagonists API Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Neurokinin Receptor Antagonists API Sales Value Share by Application (2021-2026) Table 47. Global Neurokinin Receptor Antagonists API Sales Value Share by Application (2027-2032) Table 48. Global Neurokinin Receptor Antagonists API Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 49. Global Neurokinin Receptor Antagonists API Sales by Region (2021-2026) & (Tons) Table 50. Global Neurokinin Receptor Antagonists API Sales Market Share by Region (2021-2026) Table 51. Global Neurokinin Receptor Antagonists API Sales by Region (2027-2032) & (Tons) Table 52. Global Neurokinin Receptor Antagonists API Sales Market Share by Region (2027-2032) Table 53. Global Neurokinin Receptor Antagonists API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Neurokinin Receptor Antagonists API Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Neurokinin Receptor Antagonists API Sales Value Share by Region (2021-2026) Table 56. Global Neurokinin Receptor Antagonists API Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Neurokinin Receptor Antagonists API Sales Value Share by Region (2027-2032) Table 58. Global Neurokinin Receptor Antagonists API Market Average Price (US$/Kg) by Region (2021-2026) Table 59. Global Neurokinin Receptor Antagonists API Market Average Price (US$/Kg) by Region (2027-2032) Table 60. Global Neurokinin Receptor Antagonists API Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 61. Global Neurokinin Receptor Antagonists API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 63. Global Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2026) Table 64. Global Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 65. Global Neurokinin Receptor Antagonists API Sales Market Share by Country (2027-2032) Table 66. Global Neurokinin Receptor Antagonists API Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Neurokinin Receptor Antagonists API Sales Value Market Share by Country (2021-2026) Table 68. Global Neurokinin Receptor Antagonists API Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Neurokinin Receptor Antagonists API Sales Value Market Share by Country (2027-2032) Table 70. Zhejiang Tiantai Pharmaceutical Company Information Table 71. Zhejiang Tiantai Pharmaceutical Business Overview Table 72. Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 73. Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 74. Zhejiang Tiantai Pharmaceutical Recent Development Table 75. Humanwell Pharmaceutical Company Information Table 76. Humanwell Pharmaceutical Business Overview Table 77. Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 78. Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 79. Humanwell Pharmaceutical Recent Development Table 80. Viwit Company Information Table 81. Viwit Business Overview Table 82. Viwit Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 83. Viwit Neurokinin Receptor Antagonists API Product Portfolio Table 84. Viwit Recent Development Table 85. Sichuan Qingmu Pharmaceutical Company Information Table 86. Sichuan Qingmu Pharmaceutical Business Overview Table 87. Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 88. Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 89. Sichuan Qingmu Pharmaceutical Recent Development Table 90. Kelun Pharmaceutical Company Information Table 91. Kelun Pharmaceutical Business Overview Table 92. Kelun Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 93. Kelun Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 94. Kelun Pharmaceutical Recent Development Table 95. Shandong New Time Pharmaceutical Company Information Table 96. Shandong New Time Pharmaceutical Business Overview Table 97. Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 98. Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 99. Shandong New Time Pharmaceutical Recent Development Table 100. Shandong Anxin Pharmaceutical Company Information Table 101. Shandong Anxin Pharmaceutical Business Overview Table 102. Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 103. Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 104. Shandong Anxin Pharmaceutical Recent Development Table 105. Qilu Pharmaceutical Company Information Table 106. Qilu Pharmaceutical Business Overview Table 107. Qilu Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 108. Qilu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 109. Qilu Pharmaceutical Recent Development Table 110. Luoxin Pharmaceuticals Company Information Table 111. Luoxin Pharmaceuticals Business Overview Table 112. Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 113. Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Product Portfolio Table 114. Luoxin Pharmaceuticals Recent Development Table 115. Lianyungang Runzhong Pharmaceutical Company Information Table 116. Lianyungang Runzhong Pharmaceutical Business Overview Table 117. Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 118. Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 119. Lianyungang Runzhong Pharmaceutical Recent Development Table 120. Wisdom Pharmaceutical Company Information Table 121. Wisdom Pharmaceutical Business Overview Table 122. Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 123. Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 124. Wisdom Pharmaceutical Recent Development Table 125. Hansoh Pharma Company Information Table 126. Hansoh Pharma Business Overview Table 127. Hansoh Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 128. Hansoh Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 129. Hansoh Pharma Recent Development Table 130. United Pharma Company Information Table 131. United Pharma Business Overview Table 132. United Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 133. United Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 134. United Pharma Recent Development Table 135. Hangzhou Jiuyuan Gene Engineering Company Information Table 136. Hangzhou Jiuyuan Gene Engineering Business Overview Table 137. Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 138. Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Product Portfolio Table 139. Hangzhou Jiuyuan Gene Engineering Recent Development Table 140. Beijing Sjar Technology Development Company Information Table 141. Beijing Sjar Technology Development Business Overview Table 142. Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 143. Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Product Portfolio Table 144. Beijing Sjar Technology Development Recent Development Table 145. Zydus Animal Health And Investments Company Information Table 146. Zydus Animal Health And Investments Business Overview Table 147. Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 148. Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Product Portfolio Table 149. Zydus Animal Health And Investments Recent Development Table 150. Taizhou Crene Biotechnology Company Information Table 151. Taizhou Crene Biotechnology Business Overview Table 152. Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 153. Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Product Portfolio Table 154. Taizhou Crene Biotechnology Recent Development Table 155. Solara Active Pharma Sciences Company Information Table 156. Solara Active Pharma Sciences Business Overview Table 157. Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 158. Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Product Portfolio Table 159. Solara Active Pharma Sciences Recent Development Table 160. Procos Company Information Table 161. Procos Business Overview Table 162. Procos Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 163. Procos Neurokinin Receptor Antagonists API Product Portfolio Table 164. Procos Recent Development Table 165. Piramal Pharma Company Information Table 166. Piramal Pharma Business Overview Table 167. Piramal Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 168. Piramal Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 169. Piramal Pharma Recent Development Table 170. Optimus Pharma Company Information Table 171. Optimus Pharma Business Overview Table 172. Optimus Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 173. Optimus Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 174. Optimus Pharma Recent Development Table 175. Murli Krishna Pharma Company Information Table 176. Murli Krishna Pharma Business Overview Table 177. Murli Krishna Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 178. Murli Krishna Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 179. Murli Krishna Pharma Recent Development Table 180. MSN Laboratories Company Information Table 181. MSN Laboratories Business Overview Table 182. MSN Laboratories Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 183. MSN Laboratories Neurokinin Receptor Antagonists API Product Portfolio Table 184. MSN Laboratories Recent Development Table 185. Jubilant Pharmova Company Information Table 186. Jubilant Pharmova Business Overview Table 187. Jubilant Pharmova Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 188. Jubilant Pharmova Neurokinin Receptor Antagonists API Product Portfolio Table 189. Jubilant Pharmova Recent Development Table 190. Helsinn Advanced Synthesis Company Information Table 191. Helsinn Advanced Synthesis Business Overview Table 192. Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 193. Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Product Portfolio Table 194. Helsinn Advanced Synthesis Recent Development Table 195. Glenmark Life Sciences Company Information Table 196. Glenmark Life Sciences Business Overview Table 197. Glenmark Life Sciences Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 198. Glenmark Life Sciences Neurokinin Receptor Antagonists API Product Portfolio Table 199. Glenmark Life Sciences Recent Development Table 200. Dr. Reddy's Laboratories Company Information Table 201. Dr. Reddy's Laboratories Business Overview Table 202. Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 203. Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Product Portfolio Table 204. Dr. Reddy's Laboratories Recent Development Table 205. Clearsynth Labs Company Information Table 206. Clearsynth Labs Business Overview Table 207. Clearsynth Labs Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 208. Clearsynth Labs Neurokinin Receptor Antagonists API Product Portfolio Table 209. Clearsynth Labs Recent Development Table 210. Camus Pharma Company Information Table 211. Camus Pharma Business Overview Table 212. Camus Pharma Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 213. Camus Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 214. Camus Pharma Recent Development Table 215. Andenex Company Information Table 216. Andenex Business Overview Table 217. Andenex Neurokinin Receptor Antagonists API Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 218. Andenex Neurokinin Receptor Antagonists API Product Portfolio Table 219. Andenex Recent Development Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Neurokinin Receptor Antagonists API Distributors List Table 223. Neurokinin Receptor Antagonists API Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Neurokinin Receptor Antagonists API Product Image Figure 2. Global Neurokinin Receptor Antagonists API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurokinin Receptor Antagonists API Sales (2021-2032) & (Tons) Figure 5. Global Neurokinin Receptor Antagonists API Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Neurokinin Receptor Antagonists API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Aprepitant Image Figure 10. Fezolinetant Image Figure 11. Fosaprepitant Image Figure 12. Rolapitant Image Figure 13. Maropitant Image Figure 14. Netupitant Image Figure 15. Global Neurokinin Receptor Antagonists API Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 16. Global Neurokinin Receptor Antagonists API Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Neurokinin Receptor Antagonists API Sales Volume Share by Type (2021-2032) Figure 18. Global Neurokinin Receptor Antagonists API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neurokinin Receptor Antagonists API Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Neurokinin Receptor Antagonists API Sales Value Share by Type (2021-2032) Figure 21. Injections Image Figure 22. Tablets Image Figure 23. Oral Suspension Image Figure 24. Capsules Image Figure 25. Other Image Figure 26. Global Neurokinin Receptor Antagonists API Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 27. Global Neurokinin Receptor Antagonists API Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Neurokinin Receptor Antagonists API Sales Volume Share by Application (2021-2032) Figure 29. Global Neurokinin Receptor Antagonists API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Neurokinin Receptor Antagonists API Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Neurokinin Receptor Antagonists API Sales Value Share by Application (2021-2032) Figure 32. Global Neurokinin Receptor Antagonists API Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 33. Global Neurokinin Receptor Antagonists API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Neurokinin Receptor Antagonists API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Neurokinin Receptor Antagonists API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 37. North America Neurokinin Receptor Antagonists API Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Neurokinin Receptor Antagonists API Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Neurokinin Receptor Antagonists API Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 43. South America Neurokinin Receptor Antagonists API Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Neurokinin Receptor Antagonists API Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Neurokinin Receptor Antagonists API Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Neurokinin Receptor Antagonists API Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Neurokinin Receptor Antagonists API Sales Mode & Process Figure 133. Direct Comparison with Distribution S

Scope & coverage.

Types
  • Aprepitant
  • Fezolinetant
  • Fosaprepitant
  • Rolapitant
  • Maropitant
  • Netupitant
Applications
  • Injections
  • Tablets
  • Oral Suspension
  • Capsules
  • Other
Companies covered
  • Zhejiang Tiantai Pharmaceutical
  • Humanwell Pharmaceutical
  • Viwit
  • Sichuan Qingmu Pharmaceutical
  • Kelun Pharmaceutical
  • Shandong New Time Pharmaceutical
  • Shandong Anxin Pharmaceutical
  • Qilu Pharmaceutical
  • Luoxin Pharmaceuticals
  • Lianyungang Runzhong Pharmaceutical
  • Wisdom Pharmaceutical
  • Hansoh Pharma
  • United Pharma
  • Hangzhou Jiuyuan Gene Engineering
  • Beijing Sjar Technology Development
  • Zydus Animal Health And Investments
  • Taizhou Crene Biotechnology
  • Solara Active Pharma Sciences
  • Procos
  • Piramal Pharma
  • Optimus Pharma
  • Murli Krishna Pharma
  • MSN Laboratories
  • Jubilant Pharmova
  • Helsinn Advanced Synthesis
  • Glenmark Life Sciences
  • Dr. Reddy's Laboratories
  • Clearsynth Labs
  • Camus Pharma
  • Andenex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  4. 1.2.2 Global Neurokinin Receptor Antagonists API Sales Volume (2021-2032)
  5. 1.2.3 Global Neurokinin Receptor Antagonists API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurokinin Receptor Antagonists API Market Dynamics
  1. 2.1 Neurokinin Receptor Antagonists API Industry Trends
  2. 2.2 Neurokinin Receptor Antagonists API Industry Drivers
  3. 2.3 Neurokinin Receptor Antagonists API Industry Opportunities and Challenges
  4. 2.4 Neurokinin Receptor Antagonists API Industry Restraints
3 Neurokinin Receptor Antagonists API Market by Company
  1. 3.1 Global Neurokinin Receptor Antagonists API Company Revenue Ranking in 2025
  2. 3.2 Global Neurokinin Receptor Antagonists API Revenue by Company (2021-2026)
  3. 3.3 Global Neurokinin Receptor Antagonists API Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists API Average Price by Company (2021-2026)
  5. 3.5 Global Neurokinin Receptor Antagonists API Company Ranking (2024-2026)
  6. 3.6 Global Neurokinin Receptor Antagonists API Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurokinin Receptor Antagonists API Company Product Type and Application
  8. 3.8 Global Neurokinin Receptor Antagonists API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurokinin Receptor Antagonists API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurokinin Receptor Antagonists API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurokinin Receptor Antagonists API Market by Type
  1. 4.1 Neurokinin Receptor Antagonists API Type Introduction
  2. 4.1.1 Aprepitant
  3. 4.1.2 Fezolinetant
  4. 4.1.3 Fosaprepitant
  5. 4.1.4 Rolapitant
  6. 4.1.5 Maropitant
  7. 4.1.6 Netupitant
  8. 4.2 Global Neurokinin Receptor Antagonists API Sales Volume by Type
  9. 4.2.1 Global Neurokinin Receptor Antagonists API Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Neurokinin Receptor Antagonists API Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Neurokinin Receptor Antagonists API Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Neurokinin Receptor Antagonists API Sales Value by Type
  13. 4.3.1 Global Neurokinin Receptor Antagonists API Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Neurokinin Receptor Antagonists API Sales Value by Type (2021-2032)
  15. 4.3.3 Global Neurokinin Receptor Antagonists API Sales Value Share by Type (2021-2032)
5 Neurokinin Receptor Antagonists API Market by Application
  1. 5.1 Neurokinin Receptor Antagonists API Application Introduction
  2. 5.1.1 Injections
  3. 5.1.2 Tablets
  4. 5.1.3 Oral Suspension
  5. 5.1.4 Capsules
  6. 5.1.5 Other
  7. 5.2 Global Neurokinin Receptor Antagonists API Sales Volume by Application
  8. 5.2.1 Global Neurokinin Receptor Antagonists API Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Neurokinin Receptor Antagonists API Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Neurokinin Receptor Antagonists API Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Neurokinin Receptor Antagonists API Sales Value by Application
  12. 5.3.1 Global Neurokinin Receptor Antagonists API Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Neurokinin Receptor Antagonists API Sales Value by Application (2021-2032)
  14. 5.3.3 Global Neurokinin Receptor Antagonists API Sales Value Share by Application (2021-2032)
6 Neurokinin Receptor Antagonists API Regional Sales and Value Analysis
  1. 6.1 Global Neurokinin Receptor Antagonists API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurokinin Receptor Antagonists API Sales by Region (2021-2032)
  3. 6.2.1 Global Neurokinin Receptor Antagonists API Sales by Region: 2021-2026
  4. 6.2.2 Global Neurokinin Receptor Antagonists API Sales by Region (2027-2032)
  5. 6.3 Global Neurokinin Receptor Antagonists API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurokinin Receptor Antagonists API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurokinin Receptor Antagonists API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurokinin Receptor Antagonists API Sales Value by Region (2027-2032)
  9. 6.5 Global Neurokinin Receptor Antagonists API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  12. 6.6.2 North America Neurokinin Receptor Antagonists API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  15. 6.7.2 Europe Neurokinin Receptor Antagonists API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurokinin Receptor Antagonists API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  21. 6.9.2 South America Neurokinin Receptor Antagonists API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurokinin Receptor Antagonists API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurokinin Receptor Antagonists API Sales Value Share by Country, 2025 VS 2032
7 Neurokinin Receptor Antagonists API Country-level Sales and Value Analysis
  1. 7.1 Global Neurokinin Receptor Antagonists API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurokinin Receptor Antagonists API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  4. 7.3.1 Global Neurokinin Receptor Antagonists API Sales by Country (2021-2026)
  5. 7.3.2 Global Neurokinin Receptor Antagonists API Sales by Country (2027-2032)
  6. 7.4 Global Neurokinin Receptor Antagonists API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurokinin Receptor Antagonists API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurokinin Receptor Antagonists API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurokinin Receptor Antagonists API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurokinin Receptor Antagonists API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurokinin Receptor Antagonists API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Tiantai Pharmaceutical
  2. 8.1.1 Zhejiang Tiantai Pharmaceutical Company Information
  3. 8.1.2 Zhejiang Tiantai Pharmaceutical Business Overview
  4. 8.1.3 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  6. 8.1.5 Zhejiang Tiantai Pharmaceutical Recent Developments
  7. 8.2 Humanwell Pharmaceutical
  8. 8.2.1 Humanwell Pharmaceutical Company Information
  9. 8.2.2 Humanwell Pharmaceutical Business Overview
  10. 8.2.3 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  12. 8.2.5 Humanwell Pharmaceutical Recent Developments
  13. 8.3 Viwit
  14. 8.3.1 Viwit Company Information
  15. 8.3.2 Viwit Business Overview
  16. 8.3.3 Viwit Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Viwit Neurokinin Receptor Antagonists API Product Portfolio
  18. 8.3.5 Viwit Recent Developments
  19. 8.4 Sichuan Qingmu Pharmaceutical
  20. 8.4.1 Sichuan Qingmu Pharmaceutical Company Information
  21. 8.4.2 Sichuan Qingmu Pharmaceutical Business Overview
  22. 8.4.3 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  24. 8.4.5 Sichuan Qingmu Pharmaceutical Recent Developments
  25. 8.5 Kelun Pharmaceutical
  26. 8.5.1 Kelun Pharmaceutical Company Information
  27. 8.5.2 Kelun Pharmaceutical Business Overview
  28. 8.5.3 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  30. 8.5.5 Kelun Pharmaceutical Recent Developments
  31. 8.6 Shandong New Time Pharmaceutical
  32. 8.6.1 Shandong New Time Pharmaceutical Company Information
  33. 8.6.2 Shandong New Time Pharmaceutical Business Overview
  34. 8.6.3 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  36. 8.6.5 Shandong New Time Pharmaceutical Recent Developments
  37. 8.7 Shandong Anxin Pharmaceutical
  38. 8.7.1 Shandong Anxin Pharmaceutical Company Information
  39. 8.7.2 Shandong Anxin Pharmaceutical Business Overview
  40. 8.7.3 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  42. 8.7.5 Shandong Anxin Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Luoxin Pharmaceuticals
  50. 8.9.1 Luoxin Pharmaceuticals Company Information
  51. 8.9.2 Luoxin Pharmaceuticals Business Overview
  52. 8.9.3 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Product Portfolio
  54. 8.9.5 Luoxin Pharmaceuticals Recent Developments
  55. 8.10 Lianyungang Runzhong Pharmaceutical
  56. 8.10.1 Lianyungang Runzhong Pharmaceutical Company Information
  57. 8.10.2 Lianyungang Runzhong Pharmaceutical Business Overview
  58. 8.10.3 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  60. 8.10.5 Lianyungang Runzhong Pharmaceutical Recent Developments
  61. 8.11 Wisdom Pharmaceutical
  62. 8.11.1 Wisdom Pharmaceutical Company Information
  63. 8.11.2 Wisdom Pharmaceutical Business Overview
  64. 8.11.3 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  66. 8.11.5 Wisdom Pharmaceutical Recent Developments
  67. 8.12 Hansoh Pharma
  68. 8.12.1 Hansoh Pharma Company Information
  69. 8.12.2 Hansoh Pharma Business Overview
  70. 8.12.3 Hansoh Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hansoh Pharma Neurokinin Receptor Antagonists API Product Portfolio
  72. 8.12.5 Hansoh Pharma Recent Developments
  73. 8.13 United Pharma
  74. 8.13.1 United Pharma Company Information
  75. 8.13.2 United Pharma Business Overview
  76. 8.13.3 United Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 United Pharma Neurokinin Receptor Antagonists API Product Portfolio
  78. 8.13.5 United Pharma Recent Developments
  79. 8.14 Hangzhou Jiuyuan Gene Engineering
  80. 8.14.1 Hangzhou Jiuyuan Gene Engineering Company Information
  81. 8.14.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  82. 8.14.3 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Product Portfolio
  84. 8.14.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  85. 8.15 Beijing Sjar Technology Development
  86. 8.15.1 Beijing Sjar Technology Development Company Information
  87. 8.15.2 Beijing Sjar Technology Development Business Overview
  88. 8.15.3 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Product Portfolio
  90. 8.15.5 Beijing Sjar Technology Development Recent Developments
  91. 8.16 Zydus Animal Health And Investments
  92. 8.16.1 Zydus Animal Health And Investments Company Information
  93. 8.16.2 Zydus Animal Health And Investments Business Overview
  94. 8.16.3 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Product Portfolio
  96. 8.16.5 Zydus Animal Health And Investments Recent Developments
  97. 8.17 Taizhou Crene Biotechnology
  98. 8.17.1 Taizhou Crene Biotechnology Company Information
  99. 8.17.2 Taizhou Crene Biotechnology Business Overview
  100. 8.17.3 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Product Portfolio
  102. 8.17.5 Taizhou Crene Biotechnology Recent Developments
  103. 8.18 Solara Active Pharma Sciences
  104. 8.18.1 Solara Active Pharma Sciences Company Information
  105. 8.18.2 Solara Active Pharma Sciences Business Overview
  106. 8.18.3 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Product Portfolio
  108. 8.18.5 Solara Active Pharma Sciences Recent Developments
  109. 8.19 Procos
  110. 8.19.1 Procos Company Information
  111. 8.19.2 Procos Business Overview
  112. 8.19.3 Procos Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Procos Neurokinin Receptor Antagonists API Product Portfolio
  114. 8.19.5 Procos Recent Developments
  115. 8.20 Piramal Pharma
  116. 8.20.1 Piramal Pharma Company Information
  117. 8.20.2 Piramal Pharma Business Overview
  118. 8.20.3 Piramal Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Piramal Pharma Neurokinin Receptor Antagonists API Product Portfolio
  120. 8.20.5 Piramal Pharma Recent Developments
  121. 8.21 Optimus Pharma
  122. 8.21.1 Optimus Pharma Company Information
  123. 8.21.2 Optimus Pharma Business Overview
  124. 8.21.3 Optimus Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Optimus Pharma Neurokinin Receptor Antagonists API Product Portfolio
  126. 8.21.5 Optimus Pharma Recent Developments
  127. 8.22 Murli Krishna Pharma
  128. 8.22.1 Murli Krishna Pharma Company Information
  129. 8.22.2 Murli Krishna Pharma Business Overview
  130. 8.22.3 Murli Krishna Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Murli Krishna Pharma Neurokinin Receptor Antagonists API Product Portfolio
  132. 8.22.5 Murli Krishna Pharma Recent Developments
  133. 8.23 MSN Laboratories
  134. 8.23.1 MSN Laboratories Company Information
  135. 8.23.2 MSN Laboratories Business Overview
  136. 8.23.3 MSN Laboratories Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 MSN Laboratories Neurokinin Receptor Antagonists API Product Portfolio
  138. 8.23.5 MSN Laboratories Recent Developments
  139. 8.24 Jubilant Pharmova
  140. 8.24.1 Jubilant Pharmova Company Information
  141. 8.24.2 Jubilant Pharmova Business Overview
  142. 8.24.3 Jubilant Pharmova Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Jubilant Pharmova Neurokinin Receptor Antagonists API Product Portfolio
  144. 8.24.5 Jubilant Pharmova Recent Developments
  145. 8.25 Helsinn Advanced Synthesis
  146. 8.25.1 Helsinn Advanced Synthesis Company Information
  147. 8.25.2 Helsinn Advanced Synthesis Business Overview
  148. 8.25.3 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Product Portfolio
  150. 8.25.5 Helsinn Advanced Synthesis Recent Developments
  151. 8.26 Glenmark Life Sciences
  152. 8.26.1 Glenmark Life Sciences Company Information
  153. 8.26.2 Glenmark Life Sciences Business Overview
  154. 8.26.3 Glenmark Life Sciences Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Glenmark Life Sciences Neurokinin Receptor Antagonists API Product Portfolio
  156. 8.26.5 Glenmark Life Sciences Recent Developments
  157. 8.27 Dr. Reddy's Laboratories
  158. 8.27.1 Dr. Reddy's Laboratories Company Information
  159. 8.27.2 Dr. Reddy's Laboratories Business Overview
  160. 8.27.3 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Product Portfolio
  162. 8.27.5 Dr. Reddy's Laboratories Recent Developments
  163. 8.28 Clearsynth Labs
  164. 8.28.1 Clearsynth Labs Company Information
  165. 8.28.2 Clearsynth Labs Business Overview
  166. 8.28.3 Clearsynth Labs Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Clearsynth Labs Neurokinin Receptor Antagonists API Product Portfolio
  168. 8.28.5 Clearsynth Labs Recent Developments
  169. 8.29 Camus Pharma
  170. 8.29.1 Camus Pharma Company Information
  171. 8.29.2 Camus Pharma Business Overview
  172. 8.29.3 Camus Pharma Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Camus Pharma Neurokinin Receptor Antagonists API Product Portfolio
  174. 8.29.5 Camus Pharma Recent Developments
  175. 8.30 Andenex
  176. 8.30.1 Andenex Company Information
  177. 8.30.2 Andenex Business Overview
  178. 8.30.3 Andenex Neurokinin Receptor Antagonists API Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 Andenex Neurokinin Receptor Antagonists API Product Portfolio
  180. 8.30.5 Andenex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurokinin Receptor Antagonists API Value Chain Analysis
  2. 9.1.1 Neurokinin Receptor Antagonists API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurokinin Receptor Antagonists API Sales Mode & Process
  6. 9.2 Neurokinin Receptor Antagonists API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurokinin Receptor Antagonists API Distributors
  9. 9.2.3 Neurokinin Receptor Antagonists API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst